Platform

Our drug discovery platform is fueled by an exceptional data trove, augmented with artificial intelligence/machine learning, and grounded by stem cell biology.

  • Cutting edge biological tools and cell culture
  • Aggregation of chemical structure information
  • Design novel therapeutics
  • Informed by clinical genomics

TECHNOLOGY

Medicine can now be engineered

Greenstone Biosciences are integrating high performance drug discovery, artificial intelligence, human induced pluripotent cells (hiPSCs) technology to build a drug discovery engine.

Our Expertise

AI-Driven Drug Discovery

Our sophisticated AI algorithms are designed to predict drug efficacy and safety profiles, as well as potential interactions and side effects. Our system learns and improves over time, providing a continuously evolving resource for rapid drug discovery.

Human Induced Pluripotent Stem Cells

By utilizing hiPSCs, we can mimic human physiology in the lab. This technology allows us to conduct early and accurate testing, and significantly reduces the necessity for animal testing. This approach accelerates the testing process and increases the likelihood of a successful drug candidate moving to clinical trials.

Our Approach

We combine these two powerful technologies to create an innovative drug discovery engine. This model accelerates the entire drug development process, from initial research to clinical trials, saving time and resources, and ultimately expediting the delivery of new and effective treatments to patients.

We are integrating high performance drug discovery, AI/Machine Learning computing, to achieve this new platform.

Novel therapeutics that are safe and effective for diseases with urgent unmet needs.

Paradigm-shifting drug discovery platform that accelerates therapeutics to patients.

Our novel drugs will significantly extend and improve the quality of life of patients with diseases.

iPSC BIOBANK

Unlock the power of personalized medicine

Discover the limitless potential of Greenstone’s diverse and curated collection of human induced pluripotent stem cells (iPSCs) for your research! Our iPSCs are sourced from a wide range of individuals, including both healthy and diseased individuals, providing you with a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery.

Unlock the power of patient-specific and disease-specific cells with our high-quality human iPSCs, a valuable resource that can revolutionize your scientific endeavors. We are proud to offer our iPSCs to academic investigators free of cost.

Don’t miss out on this incredible opportunity. Join the cutting-edge world of iPSC research and make groundbreaking discoveries with Greenstone’s premium human iPSCs.

Our Collaborators

Harvard | Stanford University | Boston Children’s Hospital | Duke University | Columbia University | Boston University | SUNY Downstate | University of Maryland | NCI-NIH | Clemson University | University of Central Florida | UCLA | York University | Amsterdam UMC | Hubrecht Institute | University of Bonn | Emory University | NYIT | University of Cincinnati | Medical College Wisconsin | University of Wisconsin | University of Michigan | Icahn School of Medicine at Mount Sinai | UT Southwestern | University of Kansas | Eastern Carolina University | University of Utah | Heidelberg University | Freie Universitae Berlin | QIMR Berghofer | Vilinius University | Weill Cornell Medicine | MIT | Cedars-Sinai Medical Center | University of Iowa | UCSF | University of Arkansas | Virginia Tech | Northeastern University | UCSD | Northwestern Unicersity| University of Colorado | i3s-University of Porto, Portugal | National Taiwan University | University of Leon, Spain | Max Planck Institute | UC Irvine | University of Miami | East Carolina University | Nationwide Children’s Hospital | Ohio University | Oxford University | Leiden University, Netherlands | National University of Singapore | Taipei Medical University | IRB Barcelona